Tiger BioSciences Headlines IPAWS Conference, Showcases Extensive Clinical Data in Wound Care

CONSHOHOCKEN, Pa., Nov. 14, 2025 — Tiger BioSciences served as the headline sponsor of the International Post-Acute Wound Care Society Summit (IPAWS) Conference, held November 13–14. The company presented peer-reviewed clinical information and highlighted its data-driven approach to advancing patient outcomes.

Garrett Grinsfelder, President of Tiger Wound Care, stated: "Our participation at IPAWS reflects Tiger BioSciences' dedication to advancing wound care through science, innovation, and collaboration" with leading experts. He emphasized the company's commitment to providing clinicians with solutions that improve patient outcomes.

This year, Tiger BioSciences supported five peer-reviewed retrospective manuscripts across various wound types, including chronic, surgical, and traumatic wounds. These publications showcase real-world applications of the company's cellular, acellular, and matrix-like products (CAMPs).

Additionally, the organization is conducting two randomized controlled trials evaluating ACAPatch™ and caregraFT® in combination with Standard of Care for patients with venous leg, diabetic foot, and pressure ulcers.

About Tiger BioSciences

Tiger BioSciences is a vertically integrated cell and tissue technology company involved in recovery, processing, technology development, research, and distribution of cellular, acellular, and matrix-like products. The company functions as a tissue recovery agency, processing innovator, and commercial partner to clinicians, committed to patients, providers, and donor families.